ReproCELL Inc. (4978) AI Stock Analysis

• Market Cap: ¥17.72B
• Dividend Yield: N/A
• Average Volume (3M): 2.11M
• Price to Earnings (P/E): 173.7
• Beta (1Y): 0.60
• Revenue Growth: 8.46%
• EPS Growth: 49.97%
• Country: JP
• Employees: 96
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): 1.45
• Shares Outstanding: 94,802,895
• 10 Day Avg. Volume: 1,980,240
• 30 Day Avg. Volume: 2,107,830
• PEG Ratio: 1.27
• Price to Book (P/B): 2.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -67.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ―

ReproCELL Inc.'s overall stock score reflects a company facing significant profitability and cash flow challenges despite revenue growth and a solid balance sheet. Technical indicators are mixed, and the negative valuation metrics further weigh down the score. Strategic improvements in cost management and profitability are crucial for long-term stability.

ReproCELL Inc. Business Overview & Revenue Model

Company Description

ReproCELL Inc. (4978) is a biotechnology company based in Japan that specializes in stem cell research and development. The company provides a broad range of products and services focused on drug discovery support, including human cell-based assays, reagents, and 3D cell culture products. ReproCELL's offerings cater to the pharmaceutical and academic research sectors, helping scientists and organizations accelerate their research and development processes.

How the Company Makes Money

ReproCELL Inc. generates revenue primarily through the sale of its proprietary stem cell products, reagents, and technologies that support drug discovery and regenerative medicine research. The company earns income by providing contract research services to pharmaceutical companies and academic institutions, enabling them to utilize ReproCELL's specialized technologies and expertise. Additionally, the company may form strategic partnerships or collaborations with other biotechnology companies to co-develop products or leverage mutual strengths, contributing to its revenue streams.

ReproCELL Inc. Financial Statement Overview

Summary

ReproCELL Inc. has a mixed financial performance. The company shows a strong gross profit margin and revenue growth, but faces challenges with negative profit margins and cash flow issues. The balance sheet is robust with minimal leverage, but operational inefficiencies and cash flow constraints are significant concerns.

Income Statement

ReproCELL Inc. shows a mixed income statement. Gross profit margin for TTM (Trailing-Twelve-Months) is 52.0%, indicating a solid ability to manage costs relative to revenue. However, the company faces challenges with a negative net profit margin of -4.1% and negative EBIT and EBITDA margins of -11.0% and -8.2% respectively, reflecting operational inefficiencies and high expenses. Revenue growth rate is positive at 12.0% from the previous year, a positive indicator of sales expansion.

Balance Sheet

ReproCELL Inc.'s balance sheet is relatively strong with a high equity ratio of 79.1% in TTM, showcasing financial stability and a low reliance on debt. The debt-to-equity ratio is effectively zero, indicating no leverage risk. However, the company has a negative return on equity (ROE) of -1.2%, indicating inefficiencies in generating profits from shareholders' equity.

Cash Flow

The cash flow statement highlights significant issues with cash generation. The operating cash flow to net income ratio is zero, illustrating an inability to convert income into cash flow. Free cash flow remains negative, and the lack of free cash flow growth is concerning, indicating ongoing operational cash constraints.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
2.72B	2.98B	2.43B	2.95B	2.23B	1.29B
	Gross Profit
1.41B	1.65B	1.12B	1.14B	803.44M	482.70M
	EBIT
-299.97M	-130.41M	-409.29M	-356.22M	-647.13M	-1.05B
	EBITDA
-221.65M	95.76M	8.24M	-254.59M	-513.85M	-726.20M
	Net Income Common Stockholders
-110.75M	103.25M	-31.41M	-305.31M	-575.09M	-812.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.43B	3.94B	6.57B	6.38B	4.64B	4.60B
	Total Assets
11.23B	9.67B	9.05B	8.36B	8.10B	6.05B
	Total Debt
0.00	0.00	0.00	0.00	80.00M	80.00M
	Net Debt
-3.80B	-2.82B	-2.94B	-1.91B	-2.56B	-2.52B
	Total Liabilities
2.34B	685.81M	741.03M	780.63M	844.53M	656.43M
	Stockholders Equity
8.89B	8.98B	8.31B	7.58B	7.25B	5.38B
Cash Flow		Free Cash Flow
0.00	-80.40M	-203.88M	-301.57M	-294.27M	-713.15M
	Operating Cash Flow
0.00	6.29M	-11.45M	-140.53M	-246.24M	-648.88M
	Investing Cash Flow
0.00	-796.00M	404.42M	-1.09B	-2.14B	-1.42B
	Financing Cash Flow
0.00	680.11M	544.05M	482.87M	2.38B	4.41M

ReproCELL Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 187.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Positive. The current price of 187 is above the 20-day moving average (MA) of 172.60, above the 50-day MA of 153.88, and above the 200-day MA of 135.90, indicating a bullish trend. The MACD of 9.48 indicates Negative momentum. The RSI at 62.93 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4978.

ReproCELL Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4578	77 Outperform	$3.83T	11.14	13.46%	1.52%	14.52%	156.70%
4584	55 Neutral	¥14.43B	―		―	109.03%	98.53%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
4978	49 Neutral	¥17.72B	173.73		―	8.46%	49.97%
4583	48 Neutral	¥10.48B	―		―	14.41%	27.42%
4565	45 Neutral	$83.06B	―	-3.36%	―	87.83%	75.84%
4571	40 Underperform	€9.32B	―	-26.97%	―	-30.46%	39.41%